October 2023 in “Microorganisms” This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.
6 citations
,
March 2022 in “Frontiers in drug discovery” This review summarizes 25 small molecule drugs with in vitro and in vivo data for COVID-19 treatment, highlighting their structural diversity and potential to guide future antiviral discovery.
9 citations
,
June 2022 in “Microorganisms” This review outlines the urgent need for effective therapeutic interventions against coronaviruses, as current vaccines are challenged by virus mutations, and emphasizes developing safe, affordable, and broad-spectrum antivirals for both human and porcine coronaviruses.
October 2022 in “Journal of experimental and clinical medicine” This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.